Company / Cost of Revenue
Kymera Therapeutics, Inc. Cost of Revenue History
FY2022-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cost of Revenue
$39.2M
FY2025
5-year range
$39.2M / $78.6M
FY2022-FY2025
Trend
-16.7%
vs FY2024
Sector context
#57 of 85
Health Care
What the data says
At $39M, Kymera Therapeutics, Inc.'s cost of revenue ranks #29 of 85 in the Health Care sector. Improved from $79M to $39M over the past 2 years.
Based on SEC 10-K filings.
$39M in FY2025 with a 3-year CAGR of -5.7%.
Improved from $79M to $39M over the past 2 years.
Health Care sector context is included.
Cost of Revenue over time
Growth rates
- 3-Year CAGR
- -5.7%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#29 of 85 in Health CareTop 33% of 85This company $39.2M Sector average $2.0B
▼
-98.0% below sector average
Key checks
Key Insights
- 3-year CAGR of -5.7%, indicating a declining trend.
- In FY2025, cost of revenue decreased 16.7% year-over-year.
- Ranks #57 out of 85 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score 3.27 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cost of RevenueValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $39.2M | -16.7% |
| FY2024 | $47.1M | -40.1% |
| FY2023 | $78.6M | +67.8% |
| FY2022 | $46.8M | - |
| FY2021 | - | - |
| FY2020 | - | - |
| FY2019 | - | - |
As of FY2025 · SEC Form 10-K · Last checked Jun 30, 2026